Showing results (21-30 of 32) with videos related to
Sort By:
Pageof 4
Oncotarget|October 21, 2017
HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic miceAlison K Esser, Daniel A Rauch, Jingyu Xiang, et al.Plos One|May 29, 2015
Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell TypesSarah R Amend, William C Wilson, Liang Chu, et al.Plos One|December 20, 2023
Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targetingFrancesca Fontana, Alison K Esser, Christopher Egbulefu, et al.Journal of Virology|March 23, 2022
Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19Jingyu Xiang, Mijia Lu, Min Shi, et al.Research Square|April 1, 2024
Induction of complementary immunogenic necroptosis and apoptosis cell death pathways inhibits cancer metastasis and relapseChristopher Egbulefu, Kvar Black, Xinming Su, et al.Journal of Bone Oncology|May 7, 2026
CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapyXinming Su, Takayuki Kobayashi, Jingyu Xiang, et al.Communications Biology|January 19, 2026
Radionuclide-stimulated dynamic therapy induces complementary immunogenic necroptosis and apoptosis cancer cell death pathwaysChristopher Egbulefu, Kvar Black, Xinming Su, et al.JCI Insight|October 4, 2019
HTLV-1 viral oncogene HBZ drives bone destruction in adult T cell leukemiaJingyu Xiang, Daniel A Rauch, Devra D Huey, et al.Cancer Research|September 1, 2017
Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer MetastasesMichael H Ross, Alison K Esser, Gregory C Fox, et al.Molecular Cancer Therapeutics|March 31, 2021
Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone MetastasesGregory C Fox, Xinming Su, Jennifer L Davis, et al.Pageof 4